Bioventus BVS U.S. Segment — Adjusted marketing expense

Similar metrics at other companies

NCNOReportable Segment — Adjusted sales and marketing expense

$26.88M+4.7%

FIVNReportable Segment — Adjusted Sales and Marketing Expense

$70.92M-0.5%

NETReportable Segment — Sales And Marketing Expense, Adjusted

$227.53M+24.0%

PCTYReportable Segment — Selling and Marketing Expense, Adjusted

$88.07M+6.8%

DTReportable Segment — Adjusted sales and marketing expenses

$160.1M+13.8%

CALXReportable Segment — Selling And Marketing Operating Expense, Adjusted

$56.84M+10.2%

Questions, answered.

What is Bioventus's U.S. segment — adjusted marketing expense?

Bioventus (BVS) reported U.S. segment — adjusted marketing expense of $5.89M in Q1 2026.

How has Bioventus's U.S. segment — adjusted marketing expense changed year-over-year?

Bioventus's U.S. segment — adjusted marketing expense decreased by 6.7% year-over-year, from $6.31M to $5.89M.

What is the long-term trend for Bioventus's U.S. segment — adjusted marketing expense?

Over 3 years (2022 to 2025), Bioventus's U.S. segment — adjusted marketing expense has grown at a -6.2% compound annual growth rate (CAGR), from $30.16M to $24.92M.

What does U.S. segment — adjusted marketing expense mean?

This metric tracks the adjusted expenditures dedicated to marketing campaigns, brand awareness, and product positioning within the U.S. segment. It provides insight into the company's strategy for capturing market share and supporting the commercial launch of new medical technologies.